Industry survey says costs of competing in Italy are too high
This article was originally published in Clinica
Italian medical device and diagnostic companies spent approximately 4% of their combined turnover on competitive tendering processes in 1996. This cost is unnecessarily high and can be blamed on cumbersome bureaucracy built into the system to stamp out the type of corruption which was prevalent earlier this decade.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.